DHG Pharmaceutical JSCSTC:DHG 77 Return-on-Tangible-Equity is 30.68% as of Mar. 2026, which is 31% above its 10-year median of 23.35. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,619.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 82.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. DHG Pharmaceutical JSC's annualized net income for the quarter that ended in Mar. 2026 was ₫1,262,709 Mil. DHG Pharmaceutical JSC's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₫4,116,033 Mil. Therefore, DHG Pharmaceutical JSC's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 30.68%.
The historical rank and industry rank for DHG Pharmaceutical JSC's Return-on-Tangible-Equity or its related term are showing as below:
STC:DHG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.14 Med: 23.35 Max: 28.46
Current: 23.85
During the past 13 years, DHG Pharmaceutical JSC's highest Return-on-Tangible-Equity was 28.46%. The lowest was 18.14%. And the median was 23.35%.
STC:DHG's Return-on-Tangible-Equity is ranked better than 82.5% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs STC:DHG: 23.85
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
DHG Pharmaceutical JSC Return-on-Tangible-Equity Related Terms
DHG Pharmaceutical JSC Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for DHG Pharmaceutical JSC's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STC:DHG vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 30.68% mean?
DHG Pharmaceutical JSC (STC:DHG) has a Return-on-Tangible-Equity of 30.68% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DHG Pharmaceutical JSC and its competitors. This is 31% above median its historical median of 23.35. Over the past decade, DHG Pharmaceutical JSC's Return-on-Tangible-Equity has ranged from 18.14 to 28.46. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #157 out of 897 companies in the Drug Manufacturers industry, placing it in the top 17.5%.
Is DHG Pharmaceutical JSC's Return-on-Tangible-Equity too high?
DHG Pharmaceutical JSC's current Return-on-Tangible-Equity of 30.68% is 31% above median its 10-year median of 23.35. Over the past 10 years, this metric has ranged from a low of 18.14 to a high of 28.46. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. DHG Pharmaceutical JSC's value of 30.68% is 288.4% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #157 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #157 out of 897 companies for Return-on-Tangible-Equity. This places DHG Pharmaceutical JSC in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. DHG Pharmaceutical JSC's value of 30.68% is 288.4% above this benchmark. Historically, DHG Pharmaceutical JSC's own Return-on-Tangible-Equity has ranged from 18.14 to 28.46 over the past decade. While the company's 10-year median is 23.35 vs. the industry median of 7.90, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current Return-on-Tangible-Equity of 30.68% is 288.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current Return-on-Tangible-Equity is 30.68%, which is 31% above median its own 10-year median of 23.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,619.67, compared to a current price of ₫93,600.00 — trading 17.6% below its estimated fair value. The current Return-on-Tangible-Equity is 30.68%, which is 31% above median its 10-year median of 23.35 and 288.4% above the Drug Manufacturers industry median of 7.90. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current Return-on-Tangible-Equity is 30.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫93,600.00 is trading 17.6% below its estimated GF Value™ of ₫113,619.67.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
Return-on-Tangible-Equity: 30.68% (31% above median its 10-year median of 23.35)
GF Value™: ₫113,619.67 vs. price of ₫93,600.00 (17.6% below fair value)
Industry Position: 288.4% above the Drug Manufacturers median (#157 of 897)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
